INVA · Innoviva, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Armata Pharmaceuticals investments | $457.7M | as of June 30, 2026 | — |
| Investments held by ISP Fund | $34.5M | as of June 30, 2026 | — |
| IST U.S. net product sales | $36.6M | the second quarter | — |
|
|
|||
| Royalty revenue from Glaxo Group Limited | $59.8M | the second quarter of 2026 | — |
|
|
|||
| Share repurchase amount during quarter | $31.4M | the second quarter of 2026 | — |
| Shares repurchased during quarter | 1,403,247 | the second quarter of 2026 | — |
|
|
|||
| Shares repurchased since inception of share repurchase program | 2,602,168 | through the end of the second quarter of 2026 | — |
|
|
|||
| Strategic healthcare investments | $669.5M | as of June 30, 2026 | — |
| Net product sales growth (year-over-year) | 37% | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INVA
this stock
Innoviva, Inc.
|
$1.51B | +4.9% | +62.6% | 4.8 | 9.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INVA | -0.5% | +0.0% | -6.1% | +0.0% | +4.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -0.9% | -3.0% | -19.5% | -3.0% | -7.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.